Interim Report January - September 2009

Interim Report January - September 2009

GROUP FINANCIAL PERFORMANCE JANUARY - SEPTEMBER 
• Net sales were SEK 64.1 million 
• Operating income (EBIT) was SEK 18.2 million 
• Net income after tax was SEK 10.8 million
• Results of investing activities amounted to SEK 0.0 million
• Earnings per share, basic and diluted, were SEK 0.75 
• Equity per share was SEK 38.77
• Equity/assets ratio was 80 percent

PARENT COMPANY FINANCIAL PERFORMANCE JANUARY - SEPTEMBER 
• Results of investing activities amounted to SEK 0.0 million (0.0)
• Other income totaled SEK 3.5 million (2.9) 
• Net loss after tax was SEK 10.3 million (-9.3) 

KEY EVENTS IN THE THIRD QUARTER
• Olerup SSP's entire HLA-typing range now ready for sales in the US
• Likvor's CELDATM instrument is CE marked 
• ONCOlog Medical received major order for the PatLog® system from medical
center in Prague
• ONCOlog Medical received breakthrough order for table plates in the U.S.
• LinkMed renegotiated additional purchase price for Olerup SSP
• LinkMed completed acquisition of Qiagen Vertriebs GmbH
• LinkMed strengthened its global distribution company in collaboration with
NorDiag


LINKMED CEO INGEMAR LAGERLÖFS COMMENTS ON THE THIRD QUARTER:
“The group reports a strong cash flow from operations for the first nine months
of the year. One year after the acquisition of Olerup SSP we have demonstrated
that we are successful in increasing sales for the company. AbSorber's launch in
the U.S. has 
exceeded expectations and our newly established distribution company gives
Olerup SSP and AbSorber's products the focus they need. It will be extremely
interesting to follow Likvor's launch of CELDA. This product is in demand and
will help medical centers to establish a correct diagnosis, leading to the right
treatment for NPH patients.”

For more information please contact:
Ingemar Lagerlöf, CEO, cell: +46 (0)70-873 2733 or email:
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell: +46 (0)70- 600 5364 or email:
okee.williams@linkmed.se



LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of thirteen companies, four in drug development and biotechnology and
nine in diagnostics and medical technology. The company's principal shareholders
are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB.
LinkMed is listed on the NASDAQ OMX Nordic Exchange in the Small Cap section
(ticker: LMED).